St. Vincents Hospital Report issue

Academic/Hospital Phase 1 Phase 3

Organization Overview

First Clinical Trial
2018
NCT03671590
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

St Vincents Hospital | St. Vincents Hospital

Active Ingredients

Drugs in Phase 3 Trials (1)

human fecal microbiota (1 trial)

Drugs in Phase 1 Trials (3)

tg-1701 (1 trial)

ublituximab (1 trial)

umbralisib (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 4